The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada

References

• Bevan CJ, Cree BA. Fulminant demyelinating diseases of the central nervous system. Semin Neurol 2015;35:656-66
   PubMed Web of Science ®Google Scholar
• Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:A387-94
   PubMed Web of Science ®Google Scholar
• World Health Organization. Atlas of multiple sclerosis resources in the world. Geneva, Switzerland: World Health Organization, 2008. http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf. Accessed September 16, 2013
   Google Scholar
• Hurwitz BJ. The diagnosis of multiple sclerosis and the clinical subtypes. Ann Indian Acad Neurol 2009;12:226-30
   PubMed Web of Science ®Google Scholar
• Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008;14:314-24
   PubMed Web of Science ®Google Scholar
• Zuvich RL, McCauley JL, Pericak-Vance MA, et al. Genetics and pathogenesis of multiple sclerosis. Semin Immunol 2009;21:328-33
   PubMed Web of Science ®Google Scholar
• Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler 2009;15:1175-82
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Hutchinson M, Gold R, et al. Long-term efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis according to prior therapy: Integrated analysis of the DEFINE, CONFIRM, and ENDORSE studies. Neurol 2015;84(14 Suppl):P7.234
   Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Trust. A to Z of MS: Expanded Disability Status Scale (EDSS). 29 October 2013. Letchworth Garden City, UK: Multiple Sclerosis Trust, 2013. http://www.mstrust.org.uk/atoz/edss.jsp. Accessed November 2013
   Google Scholar
• Goldenberg MM. Multiple sclerosis review. Pharm Therapeut 2012;37:175-84
   Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Society of Canada, Disease-modifying therapies, Toronto, Canada: Multiple Sclerosis Society of Canada, 2016. https://mssociety.ca/about-ms/treatments/disease-modifying-therapies-dmts. Accessed March 30, 2016
   Google Scholar
• Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625-39
   PubMed Web of Science ®Google Scholar
• Dorman E, Kansal AR, Sarda S, The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada, 2015;18:1085-91
   Google Scholar
• Kremenchutzky M, Rice GP, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006;129:584-94
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-28
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurol Scand 1970;46:493-512
   PubMed Web of Science ®Google Scholar
• NICE. Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis.NICE technology appraisal 254 (TA254). London: National Institute for Health and Care Excellence (NICE), 2012. http://www.nice.org.uk/guidance/TA254. Accessed October 11, 2013
   Google Scholar
• NICE. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (manufacturer submission to NICE). NICE technology appraisal 127 (TA127). London: National Institute for Health and Care Excellence (NICE), 2007. http://www.nice.org.uk/TA127. Accessed October 11, 2013
   Google Scholar
• Sampat MP, Berger AM, Healy BC, et al. Regional white matter atrophy–based classification of multiple sclerosis in cross-sectional and longitudinal data. Am J Neuroradiol 2009;30:1731-9
   PubMed Web of Science ®Google Scholar
• Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-50
   PubMed Web of Science ®Google Scholar
• Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
   PubMedGoogle Scholar
• Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4
   PubMed Web of Science ®Google Scholar
• Sumelahti ML, Tienari PJ, Wikstrom J, et al. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002;8:350-5
   PubMed Web of Science ®Google Scholar
• Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000;6:91-8
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012;19:e11-25
   PubMedGoogle Scholar
• NICE. Teriflunomide for treating relapsing-remitting multiple sclerosis. NICE technology appraisal 303 (TA303). London: National Institute for Health and Care Excellence (NICE), 2014. http://www.nice.org.uk/guidance/ta303. Accessed March, 2014
   Google Scholar
• Freedman MS, Patry DG, Grand'Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004;31:157-68
   PubMed Web of Science ®Google Scholar
• Ontario Ministry of Health and Long-term Care. Ontario Health Insurance (OHIP) Schedule of Benefits and Fees. Ontario, Canada: Ontario Ministry of Health and Long-term Care, 2013. http://www.health.gov.on.ca/english/providers/program/ohip/sob/sob_mn.html. Accessed December 3, 2013
   Google Scholar
• Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10:iii–iv, ix–xi, 1-160
   Web of Science ®Google Scholar
• Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522; discussion 522
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 2002;5:44-54
   PubMed Web of Science ®Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004;7:554-68
   PubMed Web of Science ®Google Scholar
• Rubio-Terres C, Aristegui Ruiz I, Medina Redondo F, et al. Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain. Farm Hosp 2003;27:159-16
   PubMedGoogle Scholar
• Darba J, Kaskens L, Sanchez-de la Rosa R, Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study, J Med Econ 2014;17:215-22
   PubMedGoogle Scholar
• Brown MG, Murray TJ, SKetris IS, et al. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. Int J Technol Assess Health Care 2000;16:751-67
   PubMed Web of Science ®Google Scholar
• Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life, J Neurol Neurosurg Psychiatry 2000;68:144-9
   PubMed Web of Science ®Google Scholar
• Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease modifying therapies in the management of multiple sclerosis for the Medicare Population. Value Health 2009;12:657-65
   PubMed Web of Science ®Google Scholar
• Rudick R, Kappos L, Polman C, et al. Long-term outcomes in natalizumab-treated patients who were free of disease activity over the 2-year affirm study. Amsterdam: 5th Joint Triennial Congress of The European and Americas Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS /ECTRIMS), 2011; Abstract no.:P513
   Google Scholar
• Arnason B, Connor P, Knappertz K, et al. Depression incidence and course in multiple sclerosis patients treated with interferon beta-1b and glatiramer acetate during the BEYOND trial. J Neurol Sci 2009;285:S211
   Google Scholar
• Bornstein MB, Miller A, Slagle S, et al. A pilot trial of cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-14
   Google Scholar
• Fox R, Miller D, Phillips T, et al. Baseline characteristics of patients enrolled in a randomized, multicenter, placebo-controlled and active comparator trial evaluating efficacy and safety of BG-12 in relapsing-remitting multiple sclerosis: the CONFIRM trial. Ontario, Canada: American Academy of Neurology (AAN) 62nd Annual Meeting, 2010; Abstract no.:P06
   Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: Results of a phase III multicenter, double- blind, placebo-controlled trial. Neurology 1995;45:1268-76
   Google Scholar
• Gold R, Kappos L, Bar-Or A, et al. Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial. Amsterdam:5th Joint Triennial Congress of The European and Americas Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS /ECTRIMS), 2011; Abstract no.:95
   Google Scholar
• Von Rosenstiel P, Hohlfeld R, Calabresi P, et al. Clinical outcomes in subgroups of patients treated with fingolimod (FTY720) or placebo: 24-month results from FREEDOMS. Mult Scler 2010;16: S143
   Google Scholar
• PRISM study group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-1504
   Google Scholar
• Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFN(beta)2-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72: 1976-83
   Google Scholar
• Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler 2011;18:418-24
   Google Scholar
• Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 2006;113:283-7
   Google Scholar
• Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): Comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 2003;9:585-91
   Google Scholar
• Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74
   Google Scholar
• Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7
   Google Scholar
• De Stefano N, Sormani MP, Stubinski B, et al. Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study. J Neurol Sci 2011; doi
   Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
   Google Scholar
• Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon-(beta) treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up. J Interferon Res 1993;13:333-40
   Google Scholar
• Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon (beta)-1a. Neurology 2000;55:185-92
   Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
   Google Scholar
• Khatri B, Barkhof F, Comi G, et al. Oral fingolimod (FTY720) reduces the rate of relapses that require steroid intervention or hospitalization compared with intramuscular interferon-1a: results from a phase III study (TRANSFORMS) in multiple sclerosis. Ontario, Canada: American Academy of Neurology (AAN) 62nd Annual Meeting, 2010; Abstract no.:P06
   Google Scholar